greengreenliving.ltd

Green Life International Co., Ltd.
Unlike typical business models, Green has been committed to four key pillars: philanthropy, commerce, education, and healing since its inception in Taiwan, building a platform for both philanthropy and consumption.

• Making philanthropy a lifestyle;

• Making every purchase meaningful.

• In 2012, the US-based NEWS Hugger Group, founded with a one-dollar fund, planted a green seed in Taiwan. From the US to Taiwan, and from Taiwan to the world. Green. Start with the heart, \\

Greenyn Biotechnology Co.,Ltd.

Insumate: 1st NDI approved Bitter Melon Peptide to improve and prevent metabolic syndromes. Antromax: 1st NDI approved solid cultured antrodia cinnamomea mycelia to enhance overall liver wellness and anti-hangovers. Zymologist: Phyto fermented goodness from 101 fruits and vegetables with low GI while rich in dietary fiber and anti-oxidants. RabenLiv: Natural extract of C. rabens for liver and overall wellbeing. RabenWhite: Natural extract of C. rabens for wrinkles, collagen contents and clinical proven anti-aging. Citrusvel: Novel Citrus Flavonoids for lipid metabolism with application among cholesterols, weight management and skin inflammation. MussLift: Marine-powered peptides to boost muscle mass and enhance physical performance. BeauSaki: Premium swiftlet-derived peptides for brighter, clearer, and more radiant skin.

GUAN XIN Biomedical

Founded in 2012 by Chairman Wen-Sheng Lee, Guan-Xin Biotech brings together Taiwan’s top biotech professionals to develop holistic health solutions. Its product lines include high-tech gold energy fabrics, premium essential oils, plant-based anti-aging skincare, patented herbal supplements, and genetic sequencing tests. In 2025, the company launched its Personal Health Management Genetic Test to help individuals identify potential health risks early.

Gwo Xi Stem Cell Applied Technology Co., Ltd.

Gwo Xi Stem Cell Company has established the R&D center for cell therapy product development at Hsinchu Biomedical Science Park since 2011.
We are committed to developing stem cell medicines that have the potential to help patients with unmet medical needs.
Our production platform fully comply with medical regulations (Good Tissue Practice, GTP) in Taiwan. There are four stem cell new drugs being put into clinical trial produced by this platform. Among them, GXNPC1 (Chronic Stroke) and GXCPC1 (Osteoarthritis) are moving forward to Phase III trial, which they use autologous ADSCs and allogeneic ADSCs, respectively.
We are establishing PIC/S GMP grade stem cell preparation factory (15,225 m2 built-out space) to put stem cell-based medicinal products into practice and progressively enlarge our production line in a scale-up level.